Abstracts ministrative data provides an opportunity to examine this use in the general population. OBJECTIVES: The study purpose was to investigate how sedative/hypnotic drugs are used in an ambulatory population. METH-ODS: A retrospective analysis of prescription claims from an integrated database. Persons with at least one prescription for a nonbarbiturate sedative/hypnotic in a 36-month sampling frame (1/1/95-12/31/97) were included. Sedative/hypnotic agents included: estazolam, ethchlorvynol, flurazepam, glutethimide, quazepam, temazepam, triazolam, and zolpidem. RESULTS: 55,086 persons had at least one claim for the drugs of interest. 58% were female, the average age was 62 years Ϯ 14.5 years, with a range of 3-104 years. 58% of those identified were 60ϩ years of age. Women were only slightly older than men (62.1 years compared to 61.8 years). The most commonly used agent during the study timeframe was zolpidem (a short-acting agent) with 58% of identified subjects having at least one claim. This was followed by temazepam (an intermediate acting agent) used by 36% of persons identified. 53% of persons using zolpidem and 36% of persons using temazepam were 60ϩ years of age. 27% of persons identified had claims evidence suggestive of single, one time acquisition of a sedative/hypnotic agent during a 12-month period of time. CONCLUSION: The majority of persons in this ambulatory population used short or intermediate acting sedative/hypnotics, for extended use. A large number of patients 60ϩ years of age rely on benzodiazepine-based agents (temazepam) that can produce daytime sedation which may decrease daytime functioning. (N ϭ 18,090) . Logistic regression models were used to investigate the predictors of not having used any medication, delaying therapy, changes in therapy, and completing one year of continuous therapy. Regression analyses were used to estimate the impact of these patterns of antipsychotic drug use on direct health care costs. RESULTS: The average annual total direct cost for communitydwelling patients with schizophrenia was $13,650 (N ϭ 18,090). Approximately 24% of patients did not use any antipsychotic drug for at least one year and consumed significantly fewer services (Ϫ$3,200). Delaying antipsychotic therapy (18%) was associated with an increase in total cost of care of $3,936 (P ϭ 0.0001). Patients who switched or augmented their initial therapy (41%) were also found to experience higher total cost of care ($4,019, P ϭ 0.0001). Continuous antipsychotic therapy (18%) was associated with significant shifts in the type of care consumed (Ϫ$1,337 in hospital costs; Ϫ$652 in nursing home costs; ϩ$1,237 in ambulatory services and ϩ$939 in other services), leaving total cost unchanged. CONCLU-SIONS: A significant proportion of patients with schizophrenia treated with traditional antipsychotic medications did not display drug utilization patterns consistent with successful drug therapy. Suboptimal drug use patterns were associated with increased direct healthcare costs. 
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MEDICAL RESOURCES CONSUMPTION BY PATIENTS WITH CHRONIC AND BREAKTHROUGH PAIN
OBJECTIVE:
This study examined medical resource consumption by patients with chronic and breakthrough pain (BTP) who were using transdermally-delivered fentanyl for the management of chronic pain. Patients were participants in a broader survey designed to collect clinical and economic information regarding their pain. METHODS: Surveys were administered to cancer and non-cancer patients with chronic and BTP to assess medical resources consumed in the past 30 days. Patients were identified from investigator practices and asked to participate in an interview. Data were collected for physician contacts, Emergency Department (ED) visits, hospitalizations, prescription use, patient work loss, and caregiver time and work loss. RESULTS: 102 patients were enrolled at the time of this analysis; 95 (93%) completed the survey. Forty (42%) were men and 55 (58%) were women. 42% reported calling and 44% visited their physician's office, averaging 1.05 telephone calls and 0.68 visits specifically because of BTP. Patients averaged 2.55 prescriptions for pain control during the period. Twelve patients (13%) reported 16 ED visits, and 11 patients (12%) reported 13 hospitalizations. Only 20 of the 95 patients (21%) were working in a paid job. Of these, 70% (14/20) reported lost work, an average of 36.9 hours during the prior 30 days, due to pain. Nearly 83% of patients reported having someone help with their personal and/or medical care. Caregivers spent an average of 77 hours helping patients. Twenty-four patients (25%) reported an average of 24 hours of caregiver work loss as a result. CONCLUSIONS: The magnitude of medical resource consumption due to pain is notable, and lost work
